Nivalis Therapeutics (Formerly Known As N30 Pharma)

39 articles about Nivalis Therapeutics (Formerly Known As N30 Pharma)

• Seattle's Impel NeuroPharma Taps Former Nivalis CEO As New Leader

  10/3/2017

• Alpine Immune Sciences Completes Merger With Nivalis

  7/25/2017

• Nivalis Announces Results Of Special Meeting Of Stockholders

  7/20/2017

• Nivalis Sets Date For Special Meeting Of Stockholders

  6/5/2017

• Nivalis Reports First Quarter 2017 Financial Results

  5/2/2017

• Ex-Dendreon CEO Returns to Biotech, Throws a Lifeline to Struggling Nivalis

  4/19/2017

• Nivalis Announces Results From Phase II Clinical Trial Of Cavosonstat Added To Ivacaftor For Treatment Of Cystic Fibrosis

  2/24/2017

• Struggling Nivalis Cuts 80% of Staff, Including CEO and CMO

  1/13/2017

• JPM17: A First: Women in Bio’s Cynthia Smith Tapped for Nivalis Board

  1/9/2017

• Nivalis Begins Exploring Strategic Alternatives and Streamlining Ops After Clinical Trial Setback

  1/4/2017

• Nivalis Decimated as Cystic Fibrosis Drug Flops in Mid-Stage Study

  11/29/2016

• 5 Biotechs Under $10 With Massive Potential

  9/8/2016

• Nivalis Therapeutics Announces First Patient Dosed In Second Phase II Study Of N91115 For Treatment Of Cystic Fibrosis

  5/17/2016

• Nivalis Therapeutics Announces Appointment Of Paul Sekhri To Its Board Of Directors

  3/2/2016

• Nivalis Therapeutics Announces First Patient Dosed In Phase II Study Of N91115 For Treatment Of Cystic Fibrosis

  12/1/2015

• Nivalis Therapeutics Announces Positive Phase Ib Results For N91115 In Patients With Cystic Fibrosis And Plans To Initiate Phase II Trial

  10/8/2015

• Nivalis Therapeutics To Present At Two Upcoming Investor Conferences

  9/4/2015

• Nivalis Therapeutics Reports Financial Results For The Second Quarter 2015

  8/4/2015

• Nivalis Therapeutics IPO Nets $88M

  6/23/2015

• Nivalis Therapeutics Set to Debut Tomorrow at $14 Per Share

  6/17/2015